![Marta Weinstock-Rosin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marta Weinstock-Rosin
Director/Board Member at Avraham Pharmaceuticals Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Yosi Ben-Dov | M | - |
The Hebrew University of Jerusalem
| 10 years |
Hermona Soreq | M | - |
The Hebrew University of Jerusalem
| - |
Bilha Shapira | F | 71 |
The Hebrew University of Jerusalem
| 15 years |
Sarah Ozacky-Lazar | M | - |
The Hebrew University of Jerusalem
| 19 years |
Itzhak Galnoor | M | - |
The Hebrew University of Jerusalem
| - |
Naomi Chazan | F | - |
The Hebrew University of Jerusalem
| - |
David Kolitz | M | 81 |
The Hebrew University of Jerusalem
| - |
Abraham Israeli | M | 70 |
The Hebrew University of Jerusalem
| 28 years |
Tamar Yassur | F | 58 |
The Hebrew University of Jerusalem
| - |
Miriyam Katz | F | 73 |
The Hebrew University of Jerusalem
| 9 years |
Uzi Vardi Zer | M | 85 |
The Hebrew University of Jerusalem
| - |
Isaiah Arkin | M | - |
The Hebrew University of Jerusalem
| 15 years |
Yaron Ilan | M | 64 |
The Hebrew University of Jerusalem
| 26 years |
Raphael Gorodetsky | M | - |
The Hebrew University of Jerusalem
| - |
Taher Nassar | M | - |
The Hebrew University of Jerusalem
| - |
Gordon Brian Stephen Hausmann | M | 78 |
The Hebrew University of Jerusalem
| - |
Moshe Vidman | M | 80 |
The Hebrew University of Jerusalem
| 29 years |
Arie Altman | M | - |
The Hebrew University of Jerusalem
| - |
Billy Shapira | F | - |
The Hebrew University of Jerusalem
| - |
Doron Shorrer | M | 41 |
The Hebrew University of Jerusalem
| - |
Saul Yedgar | M | 82 |
The Hebrew University of Jerusalem
| 42 years |
Adi Ben-Nun | M | - |
The Hebrew University of Jerusalem
| 30 years |
Zvi Wiener | M | - |
The Hebrew University of Jerusalem
| - |
Dan Yitzhak Gillerman | M | 80 |
The Hebrew University of Jerusalem
| - |
Ilan Kremer | M | 57 |
The Hebrew University of Jerusalem
| 13 years |
Amotz Agnon | M | 69 |
The Hebrew University of Jerusalem
| - |
Eugene Kandel | M | - |
The Hebrew University of Jerusalem
| 27 years |
Nechama Tzivin | F | 70 |
The Hebrew University of Jerusalem
| - |
Shimon Shitrit | M | 78 |
The Hebrew University of Jerusalem
| 28 years |
Aharon M. Eyal | M | - |
The Hebrew University of Jerusalem
| - |
Itamar Borowitz | M | 80 |
The Hebrew University of Jerusalem
| - |
Maya Liquornik | F | 68 |
The Hebrew University of Jerusalem
| - |
Udi Nissan Nisan | M | 55 |
The Hebrew University of Jerusalem
| - |
Anwar Mahmoud Rayan | M | - |
The Hebrew University of Jerusalem
| - |
Jacob Avraham Neuman | M | 75 |
The Hebrew University of Jerusalem
| 42 years |
Zeev Rotstein | M | 73 |
The Hebrew University of Jerusalem
| - |
Zvi Ioav Cabantchik | M | - |
The Hebrew University of Jerusalem
| 45 years |
Geila Rozen | M | - |
The Hebrew University of Jerusalem
| - |
Avraham Baniel | M | - |
The Hebrew University of Jerusalem
| - |
Uzi Rosen | M | 80 |
The Hebrew University of Jerusalem
| - |
Ron Hadassi | M | 59 |
The Hebrew University of Jerusalem
| - |
Leon Recanati | M | 76 |
The Hebrew University of Jerusalem
| - |
Gurion Meltzer | M | - |
The Hebrew University of Jerusalem
| - |
David Avnir | M | - |
The Hebrew University of Jerusalem
| - |
Yigal Koltin | M | - |
Avraham Pharmaceuticals Ltd.
![]() Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | - |
Yehoshua Gleitman | M | 74 |
The Hebrew University of Jerusalem
| 5 years |
I. Edelson | M | 64 |
The Hebrew University of Jerusalem
| - |
Shmuel A. Ben-Sasson | M | - |
The Hebrew University of Jerusalem
| - |
Yair Seroussi | M | 68 |
The Hebrew University of Jerusalem
| - |
Harel Beit On | M | 64 |
The Hebrew University of Jerusalem
| 6 years |
Erel Margalit | M | 63 |
The Hebrew University of Jerusalem
| - |
Richard Ziman | M | 81 |
The Hebrew University of Jerusalem
| - |
Giora Yaron | M | 75 |
The Hebrew University of Jerusalem
| - |
Martin S. Gerstel | M | 83 |
The Hebrew University of Jerusalem
| - |
Jonathan Brodie | M | 67 |
The Hebrew University of Jerusalem
| - |
Isaac Manor | M | 83 |
The Hebrew University of Jerusalem
| - |
Ofer Gonen | M | 50 |
Avraham Pharmaceuticals Ltd.
![]() Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | - |
Dan Suesskind | M | 80 |
The Hebrew University of Jerusalem
| - |
Lawrence E. Glick | M | - |
The Hebrew University of Jerusalem
| - |
Samuel Blumenfeld | M | 86 |
The Hebrew University of Jerusalem
| - |
Jacob George | M | 59 |
The Hebrew University of Jerusalem
| - |
Yaakov Naparstek | M | 75 |
The Hebrew University of Jerusalem
| - |
Alexander Levitzki | M | - |
The Hebrew University of Jerusalem
| 47 years |
Eyal Mishani | M | - |
The Hebrew University of Jerusalem
| - |
Andrew L. Shapiro | M | 56 |
The Hebrew University of Jerusalem
| - |
Hanoch Rappaport | M | - |
The Hebrew University of Jerusalem
| - |
Amnon Shashua | M | 63 |
The Hebrew University of Jerusalem
| 22 years |
Suhail Ayesh | M | - |
The Hebrew University of Jerusalem
| - |
Patricia Ohana | M | - |
The Hebrew University of Jerusalem
| - |
David Gershon | M | 59 |
The Hebrew University of Jerusalem
| 7 years |
Oded Shoseyov | M | 67 |
The Hebrew University of Jerusalem
| 34 years |
Ofer Goldberg | M | 52 |
Avraham Pharmaceuticals Ltd.
![]() Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | - |
Yoav Aharoni | M | - |
The Hebrew University of Jerusalem
| - |
Michael Schieber | M | - |
The Hebrew University of Jerusalem
| - |
Menachem Magidor | M | - |
The Hebrew University of Jerusalem
| - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Israel | 75 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marta Weinstock-Rosin
- Personal Network